Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Before anyone considers GLP-1 therapy at any dose let me be clear about who needs to avoid these medications: Personal or family history of medullary thyroid cancer or MEN-2 syndrome contraindicated History of pancreatitis may not be safe Severe gastroparesis these drugs will worsen it Pregnancy or active conception planning not recommended These are real medications with real side effects: nausea, vomiting, constipation, gallbladder problems
"Limited time offer, only 3 spots left this week" is marketing noise
Comparison to brand-name products without insurance: - Wegovy list price: ~$1,350/month - Ozempic list price (off-label for weight): ~$1,000/month - Zepbound list price: ~$1,060/month - LillyDirect self-pay Zepbound: ~$350-$550/month depending on dose - Insured commercial with savings card: $25-$550/month depending on plan and product Comparison to competitor telehealth providers: - Vitastir: roughly $200-$400/month for tirzepatide (see Vitastir tirzepatide) - Henry Meds: roughly $300/month flat for compounded tirzepatide - Ivim Health: roughly $270-$370/month depending on dose and term - Mochi Health: roughly $260-$375/month including coaching - Citizen Meds: roughly $200-$375/month (see Citizen Meds tirzepatide) Hidden cost items to ask about: - Dose escalation fees: some providers quietly charge a consultation fee each time you move up a dose tier - Supplies: syringes and alcohol swabs are usually included, but confirm this in writing - Shipping: usually free on an active subscription, sometimes $15-$30 for one-off or expedited orders - Summer cold-chain surcharges: occasionally appear during hot-weather months - Reactivation fees: some providers charge to restart after a pause Value calculation: If your insurance covers brand Wegovy, Ozempic, or Zepbound at a low copay, that is almost always the better choice because you get FDA-approved product with published stability data and a standardized manufacturing process
In a phase 2 study, adults with obesity treated with Retatrutide for 48 weeks experienced large, dose-dependent decreases in body weight, with mean reductions over 20% at higher doses
